Authors
Latest:
‘Risk-Sharing’ as a Tool for Enabling Fast Access to COVID-19 VaccinesIn a time of global pandemic, traditional vaccine procurement schemes are not fit for purpose and need to adapt to allow both governments and manufacturers the ability to manage a greater level of risk associated with rapid vaccine development and deployment.
Latest:
Gene Therapy on the Verge of Taking its Next Evolutionary StepThe shift from (ultra) rare to prevalent diseases calls for new vector manufacturing technologies
Latest:
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A RaceBig pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
Latest:
Pre-Launch Prep for Emerging Biopharmas: Data First, Then the RestMaking early commercial data and analytics decisions for launch cen future-proof their data management.
Latest:
Animating for Your Audience: The Right Visual for Your Dev StageFrom early-stage funding to commercialization, startups must adapt their strategies and messaging to effectively attract investors, build partnerships, and ultimately succeed.
Latest:
How Pharma is Reinventing Patient EngagementTuesday, October 12, 2021 at 1pm EDT | 10am PDT | 6pm BST We’re at a tipping point: patient engagement is now a key area of focus, and life sciences companies will be able to differentiate by shifting away from traditional models and embracing platforms that uniquely combine high tech with high touch. Join Andrea Heslin Smiley, President and CEO of VMS BioMarketing, the leading provider of patient adherence solutions, for a discussion on how the industry is rapidly transforming how it engages with its end customers.
Latest:
The Global Vaccine R&D Pipeline and Delivery ImplicationsThe current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
Why A New Mix of Field Skills is Crucial to Thriving in the Digital EraEvolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.
Latest:
10 Practical Regulatory Questions to Ask During a Marketing Authorization Transfer ProcessWith large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.
Latest:
HEOR: From Proving Product Value to Proving Its Own WorthThe recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Latest:
Embracing the Future: Meeting Doctors and Patients Where They Are NowPharma companies must embrace the future to advance commercialization.
Latest:
Beyond Approval: Why Your Oncology Label Determines Commercial SuccessThe stakes have never been higher.
Latest:
Creating a Digital Solution Patients and HCPs Will UseDeveloping a digital health solution that patients and HCPs will use requires creating technology that addresses unmet needs, integrates with clinical care pathways, and has strong user safeguards, writes Matt Norton.
Latest:
Why Are We Surrendering to COVID?Industry must continue research and development to combat the pandemic.
Latest:
Marketers: Physicians are People FirstUnderstanding the changes in day-to-day life for physicians during COVID and how life science executives can address them.
Latest:
Unlocking Oncology Insights - Innovations in Evidence Generation With RWE SolutionsThe rapid evolvement of precision oncology requires real-world data generated at a scale that unlocks insights that can not be provided from clinical trial evidence. Machine learning and large language models can be used to quickly identify information, supporting custom integrated real-world evidence solutions to make informed decisions.
Latest:
Omnichannel Marketing Challenges for European Life Sciences Companies: A Data Science PerspectiveAs EU brand leaders build their omnichannel customer engagement strategies, they need to address challenges in the European environment with a well-thought-out deployment plan.
Latest:
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 PandemicA look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
Latest:
Biotech’s Survival Story: Companies Bear Down for Lean YearsWhile large pharma investment in biotechs is down—as pharmas become more strategic in their selections—it is scarcely out, with the partnership dynamic between the two sides remaining strong.
Latest:
Redefine the Digital Experience for Life Science InnovationTuesday, June 29, 2021 at 2pm EDT | 1pm CDT | 11am PDT
Latest:
How Should Biotechs Strategize for 2025Strategic imperatives for biotech firms in light of the latest market dynamics and investor behaviors.
Latest:
Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of ChinaThe importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.
Latest:
China 2021: The NRDL ReadoutChina‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.
Latest:
Transforming Life Sciences R&D: The Business Case for AIWebinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT
Latest:
It’s Time for a Fresh Approach to Patient Data in Rare DiseaseCurrent practices leave much to be desired with increasing commercial needs.
